AbCellera reported third-quarter 2026 results alongside clinical and pipeline updates, led by positive Phase 2 results for its menopause-related hot-flash drug candidate ABCL635. The company also completed a $200 million share-and-warrant offering, which it says brought available liquidity to about $900 million.
The announcement highlights clinical progress and financing, but the results text provided does not include revenue, earnings, cash-burn or other quarterly financial figures.
Key details
-
ABCL635 posted positive Phase 2 results. The trial showed significant reductions in the frequency and severity of moderate and severe vasomotor symptoms, including hot flashes. AbCellera also reported a favorable tolerability profile and significant improvements in sleep and patients’ overall assessment of change.
-
Late-stage development is planned for 2027. AbCellera expects to begin late-stage development of ABCL635 for menopausal vasomotor symptoms next year.
-
The company plans to test ABCL635 in cancer-treatment-related symptoms. It is expanding development to vasomotor symptoms caused by hormone suppression associated with breast and prostate cancer treatment, with clinical trials in both groups expected to begin in 2027.
-
AbCellera completed a $200 million offering. The financing involved common shares and pre-funded warrants. The company said its available liquidity rose to approximately $900 million; the announcement text provided does not specify the offering price or the split between shares and warrants.
-
ABCL575 produced a Phase 1 top-line readout. The announcement cites the readout but does not provide its results.
-
Several other antibody programs advanced. ABCL386 and ABCL688 continued through work intended to prepare them for clinical testing. Three additional programs also moved into this stage:
- ABCL992, a longer-acting version of ABCL635 being developed for vasomotor symptoms.
- ABCL385, an investigational candidate for an undisclosed oncology indication.
- ABCL646, described as a potential first-in-class investigational antibody; further details are not provided in the announcement text.
What changes for investors
The financing strengthens AbCellera’s stated liquidity position, while the clinical updates add potential development paths for ABCL635 beyond menopausal hot flashes. The company says it met all of its 2026 corporate priorities, but the information here does not provide enough financial detail to assess its quarterly operating performance.